Info
Individualizing Targeted Therapy in Patients With CML With Specific History or Comorbidities
Risk for pleural effusions
Avoid dasatinib
Pulmonary arterial hypertension
Avoid dasatinib
QTc prolongation
Avoid nilotinib
Risk of hemorrhagic complications
Avoid dasatinib (increased risk)
Challenges with treatment adherence
Avoid nilotinib
Hepatic impairment
- Dose reduce
- bosutinib (200 mg QD) and
- ponatinib (30 mg QD)
Renal impairment
- Dose reduce imatinib (50% decrease in recommended starting dose)
- Caution with bosutinib
History of pancreatitis or at high risk for pancreatitis
- Careful monitoring with
- nilotinib
- asciminib
- ponatinib
Uncontrolled diabetes mellitus
Use nilotinib with caution
Coronary, cerebrovascular, or peripheral arterial disease
Use dasatinib, nilotinib, bosutinib, asciminib and ponatinib with caution